Related Experiment Video
Updated: Sep 20, 2026
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Newborn screening for cystic fibrosis
Richard B Parad1, Anne Marie Comeau
1Massachusetts Cystic Fibrosis Newborn Screening Program, University of Massachusetts Medical School, Department of Pediatrics, Harvard Medical School, Brigham and Women's Hospital, Children's Hospital, Boston, USA.
Insights
Newborn screening for cystic fibrosis (CF) improves growth and prevents malnutrition. Early identification of CF patients enables optimal treatment strategies and maximizes benefits from emerging therapies.
Area of Science:
- Pediatric Pulmonology
- Newborn Screening
- Genetics
Background:
- Newborn screening for cystic fibrosis (CF) is established.
- Early diagnosis allows for timely intervention.
- Long-term pulmonary benefits are increasingly recognized but require further study.
Purpose of the Study:
- To evaluate the impact of newborn screening on growth and nutritional status in CF patients.
- To explore the potential for optimizing treatment strategies in pre-symptomatic CF individuals.
- To position CF patients for maximum benefit from future therapies.
Main Methods:
- Analysis of growth and nutritional markers in screened CF newborns.
- Review of existing clinical care protocols for pre-symptomatic CF patients.
- Discussion of the potential for randomized clinical trials in this cohort.
Main Results:
- Newborn screening significantly benefits growth and prevents malnutrition in children with CF.
- Evidence for long-term pulmonary benefits is accumulating.
- Early identification facilitates enrollment in clinical trials for novel CF therapies.
Conclusions:
- Newborn screening is crucial for improving outcomes in CF.
- Standardized care for pre-symptomatic infants allows for rigorous evaluation of existing and future CF treatments.
- Identifying CF patients early maximizes their potential to benefit from emerging therapies.
Abstract:
CF newborn screening benefits growth and prevents malnutrition in children with CF. Increasing evidence suggests long-term pulmonary benefits, but these data are still accumulating. With a standardized approach to clinical care for these pre-symptomatic patients, we should be able to ask questions about the optimal treatment strategy for therapies that are currently available, perhaps through randomized clinical trials in this group. For developing therapies, Massachusetts will have identified its CF patients before they have sustained significant malnutrition and lung injury, and it may be these patients who will benefit most from therapies still on the horizon.
